AR040352A1 - Derivados de indolinfenilsulfonamida - Google Patents
Derivados de indolinfenilsulfonamidaInfo
- Publication number
- AR040352A1 AR040352A1 ARP030102373A ARP030102373A AR040352A1 AR 040352 A1 AR040352 A1 AR 040352A1 AR P030102373 A ARP030102373 A AR P030102373A AR P030102373 A ARP030102373 A AR P030102373A AR 040352 A1 AR040352 A1 AR 040352A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- group
- represents hydrogen
- alkoxy
- amino
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/96—Spiro-condensed ring systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La presente se refiere a derivados sustituidos de indolinfenilsulfonamida, a procedimientos para su preparación así como a su uso en medicamentos, especialmente como potentes compuestos activadores de PPAR-d, para la profilaxis y/o el tratamiento de enfermedades cardiovasculares, especialmente de dislipidemias y enfermedades cardíacas coronarias. Reivindicación 1: Compuestos de fórmula general (1) en la que A representa el grupo C-R11 o N, en la que R11 representa hidrógeno o alquilo (C1-4), X representa O, S o CH2, R1 representa arilo (C6-10) o heteroarilo de 5 a 10 miembros con hasta tres heteroátomos del grupo de N, O y S, que pueden estar sustituidos a su vez respectivamente una a tres veces de forma igual o distinta con sustituyentes seleccionados del grupo de halógeno, ciano, nitro, alquilo (C1-6) que a su vez puede estar sustituido con hidroxi, alcoxi (C1-6), fenoxi, benciloxi, trifluormetilo, trifluormetoxi, alquelino (C2-6), fenilo, bencilo, alquil (C1-6)tio, alquil (C1-6)sulfonilo, alcanoilo (C1-6), alcoxi (C1-6)carbonilo, carboxilo, amino, acil (C1-6)amino, mono- y dialquil (C1-6)amino y heterociclilo de 5 a 6 miembros con hasta dos heteroátomos del grupo de N, O y/o S, o representa un grupo de la fórmula (2), R2 y R3 son iguales o distintos y representan independientemente entre sí hidrógeno o alquilo (C1-6) o, conjuntamente con el átomo de carbono al que están unidos, forman un anillo cicloalquilo con unión espiro de 3 a 7 miembros, R4 representa hidrógeno o alquilo (C1-6), R5 representa hidrógeno o alquilo (C1-6), R6 representa hidrógeno o alquilo (C1-6), R7 representa hidrógeno, alquilo (C1-6), alcoxi (C1-6) o halógeno, R8 y R9 son iguales o distintos y representan independientemente entre sí hidrógeno o alquilo (C1-4), y R10 representa hidrógeno o un grupo hidrolizable que puede degradarse al correspondiente ácido carboxílico, así como sus sales, solvatos y solvatos de las sales farmacéuticamente aceptables.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10229777A DE10229777A1 (de) | 2002-07-03 | 2002-07-03 | Indolin-Phenylsulfonamid-Derivate |
Publications (1)
Publication Number | Publication Date |
---|---|
AR040352A1 true AR040352A1 (es) | 2005-03-30 |
Family
ID=29796112
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP030102373A AR040352A1 (es) | 2002-07-03 | 2003-06-30 | Derivados de indolinfenilsulfonamida |
Country Status (26)
Country | Link |
---|---|
US (1) | US20060100230A1 (es) |
EP (1) | EP1519919A1 (es) |
JP (1) | JP2005535649A (es) |
CN (1) | CN1678581A (es) |
AR (1) | AR040352A1 (es) |
AU (1) | AU2003246638A1 (es) |
BR (1) | BR0312549A (es) |
CA (1) | CA2491477A1 (es) |
DE (1) | DE10229777A1 (es) |
EC (1) | ECSP055524A (es) |
GT (1) | GT200300135A (es) |
HN (1) | HN2003000196A (es) |
HR (1) | HRP20050108A2 (es) |
IL (1) | IL165924A0 (es) |
MA (1) | MA27316A1 (es) |
MX (1) | MXPA05000133A (es) |
MY (1) | MY134641A (es) |
NO (1) | NO20050579L (es) |
NZ (1) | NZ537486A (es) |
PE (1) | PE20040645A1 (es) |
RU (1) | RU2328485C2 (es) |
TW (1) | TW200418794A (es) |
UA (1) | UA79003C2 (es) |
UY (1) | UY27878A1 (es) |
WO (1) | WO2004005253A1 (es) |
ZA (1) | ZA200500013B (es) |
Families Citing this family (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10335450A1 (de) * | 2003-08-02 | 2005-02-17 | Bayer Ag | Indolin-Sulfanilsäureamide |
DE10337839A1 (de) * | 2003-08-18 | 2005-03-17 | Bayer Healthcare Ag | Indolin-Derivate |
CA2537829A1 (en) * | 2003-09-05 | 2005-03-17 | Neurogen Corporation | Heteroaryl fused pyridines, pyrazines and pyrimidines as crf1 receptor ligands |
AR048523A1 (es) * | 2004-04-07 | 2006-05-03 | Kalypsys Inc | Compuestos con estructura de aril sulfonamida y sulfonilo como moduladores de ppar y metodos para tratar trastornos metabolicos |
ES2352085T3 (es) | 2004-05-05 | 2011-02-15 | High Point Pharmaceuticals, Llc | Nuevos compuestos, su preparación y uso. |
WO2005105736A1 (en) | 2004-05-05 | 2005-11-10 | Novo Nordisk A/S | Novel compounds, their preparation and use |
FR2869904B1 (fr) | 2004-05-07 | 2006-07-28 | Fournier S A Sa Lab | Modulateurs des recepteurs lxr |
FR2873694B1 (fr) * | 2004-07-27 | 2006-12-08 | Merck Sante Soc Par Actions Si | Nouveaux aza-indoles inhibiteurs de la mtp et apob |
CN101421258B (zh) * | 2004-10-29 | 2013-08-21 | 凯利普西斯公司 | 作为ppar调节剂的磺酰基取代的双环化合物 |
EP1805158B1 (en) * | 2004-10-29 | 2018-06-27 | Kalypsys, Inc. | Sulfonyl-substituted bicyclic compounds as modulators of ppar |
BRPI0606492A2 (pt) * | 2005-01-18 | 2009-06-30 | Novartis Ag | método de uso de compostos agonistas duplos de ppars e dispositivos para distribuição de fármacos que contêm tais compostos |
DE102005020229A1 (de) * | 2005-04-30 | 2006-11-09 | Bayer Healthcare Ag | Verwendung von Indolin-Phenylsulfonamid-Derivaten |
DE102005020230A1 (de) * | 2005-04-30 | 2006-11-09 | Bayer Healthcare Ag | Verwendung von Indolin-Phenylsulfonamid-Derivaten |
FR2886293B1 (fr) * | 2005-05-30 | 2007-08-24 | Fournier S A Sa Lab | Nouveaux composes de l'indoline |
BRPI0612730A2 (pt) | 2005-06-30 | 2010-11-30 | Novo Nordisk As | compostos, suas preparações e uso |
FR2890072A1 (fr) * | 2005-09-01 | 2007-03-02 | Fournier S A Sa Lab | Nouveaux composesde pyrrolopyridine |
US7943613B2 (en) | 2005-12-22 | 2011-05-17 | High Point Pharmaceuticals, Llc | Compounds, their preparation and use |
WO2007101864A2 (en) | 2006-03-09 | 2007-09-13 | High Point Pharmaceuticals, Llc | Compounds that modulate ppar activity, their preparation and use |
TWI315304B (en) | 2006-08-31 | 2009-10-01 | Univ Taipei Medical | Indoline-sulfonamides compounds |
EP1932843A1 (en) | 2006-12-14 | 2008-06-18 | sanofi-aventis | Sulfonyl-phenyl-2H-(1,2,4) oxadiazole-5-one derivatives, processes for their preparation and their use as pharmaceuticals |
US20080176861A1 (en) | 2007-01-23 | 2008-07-24 | Kalypsys, Inc. | Sulfonyl-substituted bicyclic compounds as ppar modulators for the treatment of non-alcoholic steatohepatitis |
TW200848021A (en) | 2007-03-06 | 2008-12-16 | Wyeth Corp | Sulfonylated heterocycles useful for modulation of the progesterone receptor |
PE20090159A1 (es) | 2007-03-08 | 2009-02-21 | Plexxikon Inc | COMPUESTOS DERIVADOS DE ACIDO INDOL-PROPIONICO COMO MODULADORES PPARs |
EP2288607B1 (en) | 2008-06-09 | 2014-09-24 | Sanofi | Sulfonamides with heterocycle and oxadiazolone headgroup, processes for their preparation and their use as pharmaceuticals |
CA2727373A1 (en) | 2008-06-09 | 2009-12-17 | Sanofi-Aventis | Annelated n-heterocyclic sulfonamides with oxadiazolone headgroup, processes for their preparation and their use as pharmaceuticals |
CN102264228A (zh) | 2008-10-22 | 2011-11-30 | 默沙东公司 | 用于抗糖尿病药的新的环状苯并咪唑衍生物 |
AU2009309037A1 (en) | 2008-10-31 | 2010-05-06 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
AU2011218830B2 (en) | 2010-02-25 | 2014-07-24 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
EA022623B1 (ru) | 2010-10-06 | 2016-02-29 | ГЛАКСОСМИТКЛАЙН ЭлЭлСи | Производные бензимидазола в качестве ингибиторов pi3-киназ |
EP2638014B1 (en) | 2010-11-08 | 2017-01-04 | Lycera Corporation | N-sulfonylated tetrahydroquinolines and related bicyclic compounds for inhibition of ror-gamma activity and the treatment of diseases |
ES2652662T3 (es) | 2011-02-25 | 2018-02-05 | Merck Sharp & Dohme Corp. | Novedosos derivados de azabencimidazol cíclicos útiles como agentes antidiabéticos |
US9657033B2 (en) * | 2012-05-08 | 2017-05-23 | Lycera Corporation | Tetrahydronaphthyridine and related bicyclic compounds for inhibition of RORγ activity and the treatment of disease |
WO2013169864A2 (en) * | 2012-05-08 | 2013-11-14 | Lycera Corporation | TETRAHYDRO[1,8]NAPHTHYRIDINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORƴ AND THE TREATMENT OF DISEASE |
AU2013296470B2 (en) | 2012-08-02 | 2016-03-17 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
MX2015010935A (es) | 2013-02-22 | 2015-10-29 | Merck Sharp & Dohme | Compuestos biciclicos antidiabeticos. |
WO2014139388A1 (en) | 2013-03-14 | 2014-09-18 | Merck Sharp & Dohme Corp. | Novel indole derivatives useful as anti-diabetic agents |
JP6192836B2 (ja) * | 2013-07-30 | 2017-09-06 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Rorcモジュレーターとしてのアザインドール化合物 |
CA2923422C (en) | 2013-09-09 | 2021-09-07 | Vtv Therapeutics Llc | Use of a ppar-delta agonist for treating muscle atrophy |
WO2015051496A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
CN103626767A (zh) * | 2013-12-04 | 2014-03-12 | 上海药明康德新药开发有限公司 | 区域选择性的氮杂吲哚及其合成方法 |
WO2015095795A1 (en) | 2013-12-20 | 2015-06-25 | Merck Sharp & Dohme Corp. | TETRAHYDRONAPHTHYRIDINE, BENZOXAZINE, AZA-BENZOXAZINE, AND RELATED BICYCLIC COMPOUNDS FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE |
WO2015095792A1 (en) | 2013-12-20 | 2015-06-25 | Merck Sharp & Dohme Corp. | Carbamate benzoxaxine propionic acids and acid derivatives for modulation of rorgamma activity and the treatment of disease |
WO2015095788A1 (en) | 2013-12-20 | 2015-06-25 | Merck Sharp & Dohme Corp. | 2-ACYLAMIDOMETHYL AND SULFONYLAMIDOMETHYL BENZOXAZINE CARBAMATES FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE |
JP2017507950A (ja) | 2014-02-27 | 2017-03-23 | リセラ・コーポレイションLycera Corporation | レチノイン酸受容体関連オーファン受容体ガンマのアゴニストを使用する養子細胞療法及び関連治療方法 |
AU2015256190B2 (en) | 2014-05-05 | 2019-08-15 | Lycera Corporation | Tetrahydroquinoline sulfonamide and related compounds for use as agonists of rory and the treatment of disease |
US10189777B2 (en) | 2014-05-05 | 2019-01-29 | Lycera Corporation | Benzenesulfonamido and related compounds for use as agonists of RORγ and the treatment of disease |
EP3256450B1 (en) | 2015-02-11 | 2020-12-02 | Merck Sharp & Dohme Corp. | Substituted pyrazole compounds as ror-gamma-t inhibitors and uses thereof |
US10421751B2 (en) | 2015-05-05 | 2019-09-24 | Lycera Corporation | Dihydro-2H-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease |
CN107980042B (zh) | 2015-06-11 | 2021-10-08 | 莱斯拉公司 | 用作RORγ激动剂和用于治疗疾病的芳基二氢-2H-苯并[b][1,4]噁嗪磺酰胺和相关化合物 |
US10344000B2 (en) | 2015-10-27 | 2019-07-09 | Merck Sharp & Dohme Corp. | Substituted bicyclic pyrazole compounds as RORgammaT inhibitors and uses thereof |
RU2018117503A (ru) | 2015-10-27 | 2019-11-28 | Мерк Шарп И Доум Корп. | ЗАМЕЩЕННЫЕ ИНДАЗОЛЬНЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ RORγТ И ИХ ПРИМЕНЕНИЕ |
WO2017075185A1 (en) | 2015-10-27 | 2017-05-04 | Merck Sharp & Dohme Corp. | Heteroaryl substituted benzoic acids as rorgammat inhibitors and uses thereof |
WO2018106518A1 (en) | 2016-12-06 | 2018-06-14 | Merck Sharp & Dohme Corp. | Antidiabetic heterocyclic compounds |
US10968232B2 (en) | 2016-12-20 | 2021-04-06 | Merck Sharp & Dohme Corp. | Antidiabetic spirochroman compounds |
CN110483509B (zh) * | 2019-09-04 | 2020-08-25 | 温州大学 | 一种合成含氮杂环衍生物的方法 |
CN110627785B (zh) * | 2019-09-19 | 2021-06-25 | 温州大学 | 一种1,5-四氢萘啶衍生物的制备方法 |
EP4077332A4 (en) * | 2019-12-18 | 2024-05-01 | Univ California | LIN28 INHIBITORS AND THEIR METHODS OF USE |
WO2023147309A1 (en) | 2022-01-25 | 2023-08-03 | Reneo Pharmaceuticals, Inc. | Use of ppar-delta agonists in the treatment of disease |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2708605A1 (fr) * | 1993-07-30 | 1995-02-10 | Sanofi Sa | Dérivés du N-sulfonylindol-2-one, leur préparation, les compositions pharmaceutiques en contenant. |
KR100266467B1 (ko) * | 1995-09-27 | 2000-10-02 | 우에노 도시오 | 설폰아미드 유도체 |
FR2757157B1 (fr) * | 1996-12-13 | 1999-12-31 | Sanofi Sa | Derives d'indolin-2-one, procede pour leur preparation et compositions pharmaceutiques les contenant |
US6787552B2 (en) * | 2000-08-11 | 2004-09-07 | Nippon Chemiphar Co., Ltd. | PPAR delta activators |
-
2002
- 2002-07-03 DE DE10229777A patent/DE10229777A1/de not_active Withdrawn
-
2003
- 2003-06-30 WO PCT/EP2003/006896 patent/WO2004005253A1/de not_active Application Discontinuation
- 2003-06-30 JP JP2004518622A patent/JP2005535649A/ja not_active Withdrawn
- 2003-06-30 AR ARP030102373A patent/AR040352A1/es not_active Application Discontinuation
- 2003-06-30 UA UAA200500952A patent/UA79003C2/uk unknown
- 2003-06-30 AU AU2003246638A patent/AU2003246638A1/en not_active Abandoned
- 2003-06-30 CN CNA038209446A patent/CN1678581A/zh active Pending
- 2003-06-30 RU RU2005102592/04A patent/RU2328485C2/ru not_active IP Right Cessation
- 2003-06-30 CA CA002491477A patent/CA2491477A1/en not_active Abandoned
- 2003-06-30 EP EP03762547A patent/EP1519919A1/de not_active Withdrawn
- 2003-06-30 BR BR0312549-1A patent/BR0312549A/pt not_active IP Right Cessation
- 2003-06-30 US US10/519,125 patent/US20060100230A1/en not_active Abandoned
- 2003-06-30 MX MXPA05000133A patent/MXPA05000133A/es unknown
- 2003-06-30 NZ NZ537486A patent/NZ537486A/en unknown
- 2003-07-01 MY MYPI20032474A patent/MY134641A/en unknown
- 2003-07-02 PE PE2003000668A patent/PE20040645A1/es not_active Application Discontinuation
- 2003-07-02 UY UY27878A patent/UY27878A1/es not_active Application Discontinuation
- 2003-07-02 GT GT200300135A patent/GT200300135A/es unknown
- 2003-07-02 TW TW092118027A patent/TW200418794A/zh unknown
- 2003-07-02 HN HN2003000196A patent/HN2003000196A/es unknown
-
2004
- 2004-12-22 IL IL16592404A patent/IL165924A0/xx unknown
-
2005
- 2005-01-03 ZA ZA200500013A patent/ZA200500013B/en unknown
- 2005-01-03 MA MA28032A patent/MA27316A1/fr unknown
- 2005-01-03 EC EC2005005524A patent/ECSP055524A/es unknown
- 2005-02-02 NO NO20050579A patent/NO20050579L/no not_active Application Discontinuation
- 2005-02-02 HR HR20050108A patent/HRP20050108A2/hr not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
US20060100230A1 (en) | 2006-05-11 |
NZ537486A (en) | 2006-07-28 |
TW200418794A (en) | 2004-10-01 |
MXPA05000133A (es) | 2005-04-11 |
IL165924A0 (en) | 2006-01-15 |
HRP20050108A2 (hr) | 2006-04-30 |
CN1678581A (zh) | 2005-10-05 |
BR0312549A (pt) | 2005-04-26 |
MA27316A1 (fr) | 2005-05-02 |
CA2491477A1 (en) | 2004-01-15 |
RU2005102592A (ru) | 2005-07-10 |
MY134641A (en) | 2007-12-31 |
ECSP055524A (es) | 2005-03-10 |
EP1519919A1 (de) | 2005-04-06 |
GT200300135A (es) | 2004-03-17 |
UA79003C2 (en) | 2007-05-10 |
AU2003246638A1 (en) | 2004-01-23 |
DE10229777A1 (de) | 2004-01-29 |
PE20040645A1 (es) | 2004-10-29 |
NO20050579L (no) | 2005-02-02 |
UY27878A1 (es) | 2004-02-27 |
JP2005535649A (ja) | 2005-11-24 |
WO2004005253A1 (de) | 2004-01-15 |
HN2003000196A (es) | 2004-11-22 |
ZA200500013B (en) | 2006-03-29 |
RU2328485C2 (ru) | 2008-07-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR040352A1 (es) | Derivados de indolinfenilsulfonamida | |
AR045113A1 (es) | Derivados sustituidos del dioxido de tiazolbenzoisotiazol, procedimiento para su preparacion y su uso | |
AR055669A1 (es) | Derivados de 3h - imidazo[4, 5 -b]piridina como inhibidores selectivos de gsk3, metodos e internediarios para su preparacion, composiciones farmaceuticas que los contienen y su uso para la elaboracion de un medicamento para el tratamiento de enfermedades neurodegenerativas y mentales. | |
AR064454A1 (es) | Derivados de pirazol con efecto inhibitorio de fgfr, metodos para su sintesis, composicion farmaceutica que los comprende, un proceso para la preparacion de la misma y su uso en la fabricacion de un medicamento para el tratamiento del cancer. | |
JP2016522172A5 (es) | ||
AR051485A1 (es) | Pirazolo pirimidinas 1,4-sustituidas como inhibidores de quinasa | |
AR034261A1 (es) | Compuestos derivados de pirazol[1,5-a]piridina; composiciones farmaceuticas, su uso en la fabricacion de medicamentos, y metodos de tratamiento de enfermedades mediadas por quinasas | |
AR055606A1 (es) | Derivados de benzoquinazolina | |
AR073932A1 (es) | Compuestos de esteres de acido 2-(aminometiliden)-4,4-difluoro-3- oxobutirico y procedimiento para su preparacion | |
AR079541A1 (es) | Compuestos sustituidos de n-(1h-indazol-4-il) imidazo (1,2-a) piridin-3-carboxamida como inhibidores de cfms | |
JP2014514360A5 (es) | ||
AR034475A1 (es) | Derivados de androstano antiinflamatorios | |
AR038686A1 (es) | Formulaciones de derivados de androstano y agonistas del adrenoreceptor beta 2 antiinflamatorios | |
AR073406A1 (es) | Aminodihidrotiazinas fusionadas con tetrahidropiranos,inhibidoras de bace1 y de la produccion de abeta amiloide, composiciones farmaceuticas que las contienen y usos de las mismas para el tratamiento de enfermedades neurodegenerativas,tales como alzheimer. | |
AR042525A1 (es) | Derivados de pirrolo-pirazoles sustituidos como inhibidores de quinasa | |
AR053774A1 (es) | Derivados de sulfonilbencimidazol. composiciones farmaceuticas. | |
NI201000123A (es) | Derivados bicíclicos de carboxamidas aza-bicíclicas, su preparación y su aplicación terapéutica. | |
AR045901A1 (es) | Glucocorticoesteroides especificos con actividades antiinflamatoria y antialergica,composiciones farmaceuticas que los contienen,y procedimientos para su preparacion, | |
AR063988A1 (es) | Derivados heterociclicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen | |
EA200700901A1 (ru) | Производные 2-амидо-4-фенилтиазола, их получение и применение в терапии | |
AR053186A1 (es) | Derivados del 1- bencil indol carboxamida | |
AR053082A1 (es) | DERIVADOS 8-PERFLUOROALQUIL-6,7,8,9-TETRAHIDROPIRIMIDO[1,2-A]PIRIMIDIN-4-ONA SUBSTITUIDOS NHIBIDORES DE GSK3BETA Y SU EMPLEO EN LA FABRICACIoN DE MEDICAMENTOS PARA EL TRATAMIENTO DE ENFERMEDADES NEURODEGENERATIVAS. | |
AR051295A1 (es) | Derivados de pirimidina y su uso | |
AR059030A1 (es) | Combinacion de derivados de triazina y estimuladores de la secrecion de insulina | |
AR059032A1 (es) | Combinacion de derivados de triazina y sensibilizadores de insulina |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |